Novavax stated on Thursday that it expects to start commercial production of a COVID-19 vaccine tailored for the Omicron coronavirus variation in January of next year, while it continues to assess whether its existing vaccine is effective against the variant.
According to the business, laboratory results due in the coming weeks will indicate if antibodies from people who have previously received Novavax's COVID-19 shot can neutralize the variation.
Novavax also announced that it has begun creating an Omicron-specific spike protein antigen and that laboratory testing of a new vaccine targeting the variant will commence in the coming weeks.
Concerns that the Omicron coronavirus type could defy protection offered by commonly used vaccines and prolong the public health crisis have shook markets and created global worry.
Other vaccine companies, such as Moderna and Pfizer, have started developing Omicron-specific COVID-19 injections.
In early November, Indonesia became the first country to approve Novavax's COVID-19 vaccine for emergency use, followed by the Philippines.